TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04497519
Drug: inhaled hydroxychloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascending dose of iHCQ
Study: NCT03611699
Drug: Umeclidinium / Vilanterol Dry Powder Inhaler
Normalized name: umeclidinium / vilanterol Dry Powder Inhaler
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: umeclidinium/vilanterol dry powder inhaler
Study: NCT02054182
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
Study: NCT03585764
Drug: MOv19-BBz CAR T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
Study: NCT00746499
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg raltegravir BID x 7 days
Study: NCT00974220
Drug: normal saline (placebo)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, 0.9% saline solution
Study: NCT04097028
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00804154
Drug: Intrathecal Resiniferatoxin
Normalized name: beractant
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
Study: NCT02952508
Drug: Iopofosine I 131 single dose
Normalized name: Iopofosine I-131
DrugBank: Iopofosine I-131 (DB15244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical
Study: NCT02952508
Drug: Iopofosine I 131 multiple dose
Normalized name: Iopofosine I-131
DrugBank: Iopofosine I-131 (DB15244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical
Study: NCT02952508
Drug: Iopofosine I 131 fractionated dose
Normalized name: Iopofosine I-131
DrugBank: Iopofosine I-131 (DB15244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical
Study: NCT03782207
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
Study: NCT01054079
Drug: cinacalcet hydrochloride
Normalized name: Cinacalcet Hydrochloride
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00989989
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
Study: NCT00989989
Drug: Sham ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
Study: NCT00032084
Drug: bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/day on Days 1-3, 300 mg/day on Day 4-77
Study: NCT00032084
Drug: nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
Study: NCT00620061
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 mcg capsules for oral administration
Study: NCT00712348
Drug: Taliglucerase alfa
Normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion every 2 weeks
Study: NCT04296175
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg/m2, d1 every 2 or 3 weeks
Study: NCT04296175
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg/m2,d1,d8,d15, every 3 weeks
Study: NCT04296175
Drug: ddEpirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg/m2, d1 every 2 weeks
Study: NCT04296175
Drug: Paclitaxel(with carbo)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg/m2,d1,d8,d15, every 4 weeks
Study: NCT04296175
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=2,d1,d8,d15, every 4 weeks
Study: NCT02464696
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IPS cohort only
Study: NCT03022097
Drug: Aclidinium bromide/formoterol Fixed-Dose Combination
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
Study: NCT03022097
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
Study: NCT03022097
Drug: Formoterol Fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
Study: NCT03710421
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04602533
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
Study: NCT00096161
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00096161
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00096161
Drug: Pentostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04084366
Drug: OBI-999
Normalized name: OBI-999
DrugBank: OBI-999 (DB17356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
Study: NCT04084366
Drug: OBI-999
Normalized name: OBI-999
DrugBank: OBI-999 (DB17356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
Study: NCT04444921
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04444921
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01746836
Drug: Ponatinib Hydrochloride
Normalized name: Ponatinib Hydrochloride
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose: 30 mg by mouth once a day.
Study: NCT04444492
Drug: Ranibizumab Injection
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: initial three injections of Ranibizumab - afterwards pro re nata monthly
Study: NCT02922764
Drug: RGX-104
Normalized name: RGX-111
DrugBank: RGX-111 (DB17632)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02922764
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02922764
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02922764
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02922764
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02922764
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02979093
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All women will receive a nasal spray containing oxytocin.
Study: NCT02378298
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
Study: NCT04519619
Drug: Aflibercept (Eylea, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration by intravitreal injection
Study: NCT01946529
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).
Study: NCT01946529
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants \> 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.
Study: NCT01946529
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children \> 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.
Study: NCT01946529
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.
Study: NCT01946529
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.
Study: NCT01946529
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
Study: NCT01946529
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage and route of administration: 90 mg/m\^2/dose PO BID
Study: NCT03192020
Drug: Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
Study: NCT03893903
Drug: IDH1R132H peptide vaccine
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks.
Study: NCT03893903
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression.
Study: NCT03155646
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
Study: NCT03155646
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
Study: NCT03155646
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
Study: NCT02381379
Drug: Peginterferon-α-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
Study: NCT04196530
Drug: BDB001 (EIK1001)
Normalized name: BDB001
DrugBank: BDB-001 (DB16480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDB001 (EIK1001) is an immunotherapy agent.
Study: NCT04196530
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Study: NCT01709331
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
Study: NCT03215719
Drug: Cisplatinum
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care chemotherapy
Study: NCT01065454
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
Study: NCT01065454
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: up to 1 mg three times a day (increasing from 0.5 to 1 mg)
Study: NCT01065454
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fixed 0.5 mg three times a day
Study: NCT01709331
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
Study: NCT00772447
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg/kg IV ; Q 24 hr (once every 24 hours)
Study: NCT00772447
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~- 1 g every 6 hours or 2 g every 8 hours
Study: NCT02525549
Drug: Adapalene and Benzoyl Peroxide Gel
Normalized name: Adapalene and Benzoyl Peroxide Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02525549
Drug: Adapalene and Benzoyl Peroxide Gel (Reference)
Normalized name: adapalene / benzoyl peroxide
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02064010
Drug: SNC-102
Normalized name: Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo
DrugBank: Cinpanemab (DB16127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
Study: NCT03320772
Drug: TMVP1-ICG
Normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of SLN
Study: NCT03320772
Drug: ICG
Normalized name: ICG136
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of SLN
Study: NCT01148511
Drug: Ranibizumab 0.5 mg
Normalized name: ranibizumab 0.5 MG in 0.05 ML Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab was supplied as a sterile solution in sealed glass vials.
Study: NCT03838601
Drug: MET-4
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
Study: NCT03671811
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01746979
Drug: TH-302
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study: NCT01746979
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study: NCT00352846
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg by mouth daily
Study: NCT00352846
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200 mg by mouth daily
Study: NCT00650858
Drug: tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
Study: NCT02885961
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-coagulant
Study: NCT00168636
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02503358
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02503358
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01089413
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As prescribed by physician
Study: NCT03883919
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Standard of care drug
Study: NCT03883919
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Standard of care drug
Study: NCT03883919
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Investigational drug
Study: NCT00588172
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000mg bid for 1 week
Study: NCT01469143
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
Study: NCT01469143
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
Study: NCT03905265
Drug: Moxidectin Oral Product
Normalized name: moxidectin Oral Product
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required